SMMT Summit Therapeutics PLC
Company Analysis
Latest News
Summit Therapeutics PLC Q2 2026 Earnings Preview: What Analysts Expect on July 23, 2026
Analysts expect Summit Therapeutics to report a Q2 2026 loss of $0.26 per share on revenue of approximately $0.11 million, with the stock currently trading at...
🟢 Summit Therapeutics is trading 4.3% up today in a rebound from prior declines
Summit Therapeutics is trading at $14.08 (up 4.3%) as the stock rebounds from prior declines linked to ivonescimab trial and regulatory overhangs. • The move...
🔴 Summit Therapeutics is trading 10.2% down
Summit Therapeutics is trading at $13.54, down 10.2% from a comparison close of $15.07 during regular trading. This is a price-action follow-up, so a separate...
🔴 Summit Therapeutics is trading 4.1% down today on lingering trial and earnings concerns
Summit Therapeutics is trading at $14.45 (down 4.1%) as shares continue to drift lower following recent clinical and financial setbacks. • Investor sentiment...
🟢 SMMT extends move to 6.9% up
SMMT is trading at $15.37, up 6.9% versus the comparison close of $14.38 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 SMMT is trading 4% up today after recent biotech volatility and prior trial news
SMMT is trading 4% up now at $14.96 after a stretch of volatile biotech trading and earlier news around its ivonescimab program. Recent weeks saw sharp moves...
Summit Therapeutics rated Buy, citing short squeeze potential and upcoming catalysts
Seeking Alpha initiated coverage on Summit Therapeutics with a cautious Buy rating. The analysis describes the company as a volatile, single-asset entity...
🟢 Summit Therapeutics PLC up 4.03% on recent $50M insider investment and withdrawn equity offering
Summit Therapeutics PLC is trading at $14.44 (+4.03%) today, fueled by a series of recent positive company-specific developments. • A director, Robert W....